semaglutide autoimmune GLP-1 Agonists in Disease Semaglutide and Autoimmune Diseases (Ozempic
Description
Management of diabetes in pregnancy: Standards of Care in Diabetes 2026
Neuner, C
At 68 weeks, 52.1% of patients were on a 2.4 mg dose of semaglutide
Nausea, vomiting, and diarrhea were most often reported during periods of dose escalation
When combined with diet and exercise, these tablets can encourage steady weight loss for adults
Headache and fatigue can occur, especially during dose increases
